)
Product Pipeline
Focused on Innovation
Our product portfolio focuses on innovation in new products, improved products and manufacturing expertise thereby ensuring our continued growth. Our balanced research and development portfolio is divided into two categories: life cycle management/market development and new product development. Lifecycle management ensures continuous product improvement by maintaining and increasing competitiveness within our existing product range. Market development brings therapies to new markets and new indications by maximizing market opportunities for our existing product range. New product development creates specialty therapies to treat life-threatening diseases. It ensures long-term growth primarily through projects aligned with our current marketing channels.
Core Capabilities
as demonstrated in our product pipeline
Research / Pre-Clinical
Clinical Development
Registration / Post-Launch
CSL964 AAT GvHD
Prevention of acute Graft versus Host Disease (GVHD) in high-risk adolescent and adult patients receiving an allogeneic hematopoietic cell transplant (HCT). Treatment of steroid refractory acute GVHD in adolescent and adult patients
CSL842 C1-INH AMR
C1-esterase inhibitor (C1-INH) for the treatment of refractory antibody mediated rejection (rAMR) in adult renal transplant recipients.
HIZENTRA® IIM
HIZENTRA™, 20% subcutaneous immunoglobulin, for the treatment and long-term maintenance therapy of adults with Idiopathic Inflammatory Myopathies (IIM).
CSL964 AAT GvHD
Prevention of acute Graft versus Host Disease (GVHD) in high-risk adolescent and adult patients receiving an allogeneic hematopoietic cell transplant (HCT). Treatment of steroid refractory acute GVHD in adolescent and adult patients
CSL842 C1-INH AMR
C1-esterase inhibitor (C1-INH) for the treatment of refractory antibody mediated rejection (rAMR) in adult renal transplant recipients.
HIZENTRA® IIM
HIZENTRA™, 20% subcutaneous immunoglobulin, for the treatment and long-term maintenance therapy of adults with Idiopathic Inflammatory Myopathies (IIM).
HIZENTRA® CIDP US, Japan, EU, AUS
The first 20% high concentration low volume subcutaneous immunoglobulin for convenient self administration. Approval for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
PRIVIGEN® PID Japan
PRIVIGEN®, 10% intravenous immunoglobulin, for the treatment of primary immune deficiency (PID) indications in Japan.
PRIVIGEN® CIDP US, Japan
PRIVIGEN®, 10% intravenous immunoglobulin, approved for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability.
CSL830 C1-INH Subcut, EU
Self-administered subcutaneous C1-esterase inhibitor (human), for routine prophylaxis to prevent HAE attacks in adolescent and adult patients.
HAEGARDA® US
Self-administered subcutaneous C1-esterase inhibitor (human), for routine prophylaxis to prevent HAE attacks in adolescent and adult patients.
KCENTRA® Japan
Lyophilized formulation of plasma-derived concentrate of coagulation factors II, VII, IX, X, Protein C and Protein S used as intravenous administration in patients with acquired deficiency of coagulation factors due to vitamin K antagonist (e.g. Warfarin) therapy.
AFLURIA® QIV 5+ US, AUS
Seasonal egg-based split viron quadrivalent influenza vaccine offering protection against four different strains
AFLURIA® QIV 6m+ US
Seasonal egg-based split viron quadrivalent influenza vaccine registered in the US for use in children 6 months of age and older.
AFLURIA® QIV 6m-4 yr AUS
Seasonal egg-based split viron quadrivalent influenza vaccine registered in Australia for use in children 6 months – 4 years of age
FLUAD® aTIV 65+ UK, US, AUS
Seasonal egg-based adjuvanted trivalent influenza vaccine offering protection against three different strains
FLUCELVAX® QIV 4+ US
Seasonal cell culture-based quadrivalent influenza vaccine offering protection against four different strains for use in children 4 years of age and older.
CSL730* rFc Multimer
Novel recombinant human Fc multimer for treatment of patients with immune complex-mediated autoimmune diseases. Developed in collaboration with Momenta Pharmaceuticals.
* Partnered Project
CSL312 Anti-FXIIa in HAE
A humanised anti-factor XIIa monoclonal antibody in development for use in multiple indications including as a subcutaneous therapy for HAE with the potential for administration once every two to three weeks.
CSL324 Anti-G-CSFR
Recombinant Monoclonal Antibody against the cytokine granulocyte colony stimulating factor receptor for the potential development of a new class of drugs that targets arthritis and other inflammatory diseases.
CSL346 Anti-VEGF-B
A humanised mAb that antagonises VEGF-B and is administered via subcutaneous injection either as a standalone therapy or in combination with other agents for the potential treatment of diabetic nephropathy, or other conditions associated with aberrant lipid metabolism.
CSL112 Apo-A1
Novel apolipoprotein A-I infusion therapy developed to reduce the high incidence of early recurrent cardiovascular events that occur in the weeks to months following a heart attack.
CSL334 IL-13R* ASLAN
Monoclonal antibody targeting IL-13Rα1 for the treatment of atopic dermatitis. Licensed to ASLAN Pharmaceuticals.
* Partnered Project
FLUAD® QIV 65+
Seasonal egg-based, adjuvanted quadrivalent influenza vaccine offering protection against four different strains
Pre-Pandemic Vaccine (aH5N1c)
Pandemic Influenza vaccine, cell based, MF59® adjuvanted, offering protection against H5N1
Clazakizumab Anti IL-6 Vitaeris*
Humanized recombinant monoclonal antibody that binds to and inhibits Interleukin-6 (IL-6) as a therapeutic option for solid organ transplant rejection. Development in collaboration with Vitaeris Inc.
* Partnered Project
CSL630 pdFVIII Ruide
Plasma-derived Human Factor VIII manufactured in China through the acquisition of Wuhan Zhong Yuan Rui De Biological Products Co. Ltd. (Ruide).
CSL730* rFc Multimer
Novel recombinant human Fc multimer for treatment of patients with immune complex-mediated autoimmune diseases. Developed in collaboration with Momenta Pharmaceuticals.
* Partnered Project
CSL312 Anti-FXIIa in HAE
A humanised anti-factor XIIa monoclonal antibody in development for use in multiple indications including as a subcutaneous therapy for HAE with the potential for administration once every two to three weeks.
CSL324 Anti-G-CSFR
Recombinant Monoclonal Antibody against the cytokine granulocyte colony stimulating factor receptor for the potential development of a new class of drugs that targets arthritis and other inflammatory diseases.
CSL346 Anti-VEGF-B
A humanised mAb that antagonises VEGF-B and is administered via subcutaneous injection either as a standalone therapy or in combination with other agents for the potential treatment of diabetic nephropathy, or other conditions associated with aberrant lipid metabolism.
CSL112 Apo-A1
Novel apolipoprotein A-I infusion therapy developed to reduce the high incidence of early recurrent cardiovascular events that occur in the weeks to months following a heart attack.
CSL334 IL-13R* ASLAN
Monoclonal antibody targeting IL-13Rα1 for the treatment of atopic dermatitis. Licensed to ASLAN Pharmaceuticals.
* Partnered Project
FLUAD® QIV 65+
Seasonal egg-based, adjuvanted quadrivalent influenza vaccine offering protection against four different strains
Pre-Pandemic Vaccine (aH5N1c)
Pandemic Influenza vaccine, cell based, MF59® adjuvanted, offering protection against H5N1
Clazakizumab Anti IL-6 Vitaeris*
Humanized recombinant monoclonal antibody that binds to and inhibits Interleukin-6 (IL-6) as a therapeutic option for solid organ transplant rejection. Development in collaboration with Vitaeris Inc.
* Partnered Project
CSL630 pdFVIII Ruide
Plasma-derived Human Factor VIII manufactured in China through the acquisition of Wuhan Zhong Yuan Rui De Biological Products Co. Ltd. (Ruide).
IDELVION®
Novel, long-acting albumin fusion protein linking recombinant coagulation factor IX with recombinant albumin for the treatment of haemophilia B. Delivers high-level protection with up to 14-day dosing in appropriate patients.
AFSTYLA®
Novel long-lasting recombinant factor VIII single-chain therapy for adults and children with haemophilia A.